Cargando…
Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study
This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for heart failure or a history of heart failure and a lower risk of bleeding. A...
Autores principales: | Spyropoulos, Alex C., Raskob, Gary E., Spiro, Theodore E., Lu, Wentao, De Sanctis, Yoriko, Albanese, John, Mebazaa, Alexandre, Barnathan, Elliot S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546607/ https://www.ncbi.nlm.nih.gov/pubmed/36299620 http://dx.doi.org/10.1055/a-1926-2489 |
Ejemplares similares
-
Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
por: Raskob, Gary E., et al.
Publicado: (2021) -
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the
MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2019) -
Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis
por: Spyropoulos, Alex C., et al.
Publicado: (2020) -
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011) -
Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)